<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;ff=20240509121035&amp;utm_source=Chrome&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;ff=20240509121035&amp;utm_source=Chrome&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 09 May 2024 16:10:37 +0000</lastbuilddate>
<pubDate>Wed, 08 May 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Anticoagulation for Atrial Fibrillation in Patients With Surgically Occluded Left Atrial Appendage</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38719372/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240509121035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 14;83(19):1936-1938. doi: 10.1016/j.jacc.2024.03.376.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38719372/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240509121035&v=2.18.0.post9+e462414">38719372</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.376>10.1016/j.jacc.2024.03.376</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38719372</guid>
<pubDate>Wed, 08 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Tarun Chakravarty</dc:creator>
<dc:creator>Aum Solanki</dc:creator>
<dc:creator>Neel Bhardwaj</dc:creator>
<dc:creator>Vivek Patel</dc:creator>
<dc:creator>Joanna Chikwe</dc:creator>
<dc:creator>Raj R Makkar</dc:creator>
<dc:date>2024-05-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Anticoagulation for Atrial Fibrillation in Patients With Surgically Occluded Left Atrial Appendage</dc:title>
<dc:identifier>pmid:38719372</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.376</dc:identifier>
</item>
<item>
<title>Postmyocardial Infarction Ventricular Aneurysm: JACC Focus Seminar 5/5</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38719371/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240509121035&amp;v=2.18.0.post9+e462414
      <description>Ventricular aneurysm represents a rare complication of transmural acute myocardial infarction, although other cardiac, congenital, or metabolic diseases may also predispose to such condition. Ventricular expansion includes all the cardiac layers, usually with a large segment involved. Adverse events include recurrent angina, reduced ventricular stroke volume with congestive heart failure, mitral regurgitation, thromboembolism, and ventricular arrhythmias. Multimodality imaging is paramount to...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 14;83(19):1917-1935. doi: 10.1016/j.jacc.2024.02.044.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Ventricular aneurysm represents a rare complication of transmural acute myocardial infarction, although other cardiac, congenital, or metabolic diseases may also predispose to such condition. Ventricular expansion includes all the cardiac layers, usually with a large segment involved. Adverse events include recurrent angina, reduced ventricular stroke volume with congestive heart failure, mitral regurgitation, thromboembolism, and ventricular arrhythmias. Multimodality imaging is paramount to provide comprehensive assessment, allowing for appropriate therapeutic decision-making. When indicated, surgical intervention remains the gold standard, although additional therapy (heart failure, anticoagulation, and advanced antiarrhythmic treatment) might be required. However, the STICH (Surgical Treatment for Ischemic Heart Failure) trial did not show any advantage from adding surgical ventricular reconstruction to coronary artery bypass surgery in terms of survival, rehospitalization or symptoms, compared with revascularization alone. Finally, implantable cardiac defibrillator may reduce the risk of fatal arrhythmias.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38719371/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240509121035&v=2.18.0.post9+e462414">38719371</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.044>10.1016/j.jacc.2024.02.044</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38719371</guid>
<pubDate>Wed, 08 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Roberto Lorusso</dc:creator>
<dc:creator>Matteo Matteucci</dc:creator>
<dc:creator>Stamatios Lerakis</dc:creator>
<dc:creator>Daniele Ronco</dc:creator>
<dc:creator>Lorenzo Menicanti</dc:creator>
<dc:creator>Samin K Sharma</dc:creator>
<dc:creator>Pedro R Moreno</dc:creator>
<dc:date>2024-05-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Postmyocardial Infarction Ventricular Aneurysm: JACC Focus Seminar 5/5</dc:title>
<dc:identifier>pmid:38719371</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.044</dc:identifier>
</item>
<item>
<title>Ventricular Pseudoaneurysm and Free Wall Rupture After Acute Myocardial Infarction: JACC Focus Seminar 4/5</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38719370/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240509121035&amp;v=2.18.0.post9+e462414
      <description>Postinfarction ventricular free-wall rupture is a rare mechanical complication, accounting for &lt;0.01% to 0.02% of cases. As an often-catastrophic event, death typically ensues within minutes due to sudden massive hemopericardium resulting in cardiac tamponade. Early recognition is pivotal, and may allow for pericardial drainage and open surgical repair as the only emergent life-saving procedure. In cases of contained rupture with pseudo-aneurysm (PSA) formation, hospitalization with subsequent...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 14;83(19):1902-1916. doi: 10.1016/j.jacc.2023.10.054.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Postinfarction ventricular free-wall rupture is a rare mechanical complication, accounting for &lt;0.01% to 0.02% of cases. As an often-catastrophic event, death typically ensues within minutes due to sudden massive hemopericardium resulting in cardiac tamponade. Early recognition is pivotal, and may allow for pericardial drainage and open surgical repair as the only emergent life-saving procedure. In cases of contained rupture with pseudo-aneurysm (PSA) formation, hospitalization with subsequent early surgical intervention is warranted. Not uncommonly, PSA may go unrecognized in asymptomatic patients and diagnosed late during subsequent cardiac imaging. In these patients, the unsettling risk of complete rupture demands early surgical repair. Novel developments, in the field of transcatheter-based therapies and multimodality imaging, have enabled percutaneous PSA repair as a feasible alternate strategy for patients at high or prohibitive surgical risk. Contemporary advancements in the diagnosis and treatment of postmyocardial infarction ventricular free-wall rupture and PSA are provided in this review.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38719370/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240509121035&v=2.18.0.post9+e462414">38719370</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.054>10.1016/j.jacc.2023.10.054</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38719370</guid>
<pubDate>Wed, 08 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Roberto Lorusso</dc:creator>
<dc:creator>Roberto J Cubeddu</dc:creator>
<dc:creator>Matteo Matteucci</dc:creator>
<dc:creator>Daniele Ronco</dc:creator>
<dc:creator>Pedro R Moreno</dc:creator>
<dc:date>2024-05-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Ventricular Pseudoaneurysm and Free Wall Rupture After Acute Myocardial Infarction: JACC Focus Seminar 4/5</dc:title>
<dc:identifier>pmid:38719370</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.054</dc:identifier>
</item>
<item>
<title>Ventricular Septal Rupture After Myocardial Infarction: JACC Focus Seminar 3/5</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38719369/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240509121035&amp;v=2.18.0.post9+e462414
      <description>Ventricular septal rupture remains a dreadful complication of acute myocardial infarction. Although less commonly observed than during the prethrombolytic era, the condition remains complex and is often associated with refractory cardiogenic shock and death. Corrective surgery, although superior to medical treatment, has been associated with high perioperative morbidity and mortality. Transcatheter closure techniques are less invasive to surgery and offer a valuable alternative, particularly in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 14;83(19):1886-1901. doi: 10.1016/j.jacc.2024.01.041.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Ventricular septal rupture remains a dreadful complication of acute myocardial infarction. Although less commonly observed than during the prethrombolytic era, the condition remains complex and is often associated with refractory cardiogenic shock and death. Corrective surgery, although superior to medical treatment, has been associated with high perioperative morbidity and mortality. Transcatheter closure techniques are less invasive to surgery and offer a valuable alternative, particularly in patients with cardiogenic shock. In these patients, percutaneous mechanical circulatory support represents a novel opportunity for immediate stabilization and preserved end-organ function. Multimodality imaging can identify favorable septal anatomy for the most appropriate type of repair. The heart team approach will define optimal timing for surgery vs percutaneous repair. Emerging concepts are proposed for a deferred treatment approach, including orthotropic heart transplantation in ideal candidates. Finally, for futile situations, palliative care experts and a medical ethics team will provide the best options for end-of-life clinical decision making.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38719369/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240509121035&v=2.18.0.post9+e462414">38719369</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.041>10.1016/j.jacc.2024.01.041</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38719369</guid>
<pubDate>Wed, 08 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Roberto J Cubeddu</dc:creator>
<dc:creator>Roberto Lorusso</dc:creator>
<dc:creator>Daniele Ronco</dc:creator>
<dc:creator>Matteo Matteucci</dc:creator>
<dc:creator>Michael S Axline</dc:creator>
<dc:creator>Pedro R Moreno</dc:creator>
<dc:date>2024-05-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Ventricular Septal Rupture After Myocardial Infarction: JACC Focus Seminar 3/5</dc:title>
<dc:identifier>pmid:38719369</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.041</dc:identifier>
</item>
<item>
<title>Long-Term Cardiovascular Risks of Psychostimulant Drugs for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38719368/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240509121035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 14;83(19):1883-1885. doi: 10.1016/j.jacc.2024.03.409.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38719368/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240509121035&v=2.18.0.post9+e462414">38719368</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.409>10.1016/j.jacc.2024.03.409</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38719368</guid>
<pubDate>Wed, 08 May 2024 06:00:00 -0400</pubDate>
<dc:creator>G Caleb Alexander</dc:creator>
<dc:creator>Thomas J Moore</dc:creator>
<dc:creator>Eric P Brass</dc:creator>
<dc:date>2024-05-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Long-Term Cardiovascular Risks of Psychostimulant Drugs for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)</dc:title>
<dc:identifier>pmid:38719368</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.409</dc:identifier>
</item>
<item>
<title>Long-Term Cardiovascular Risk Associated With Treatment of Attention-Deficit/Hyperactivity Disorder in Adults</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38719367/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240509121035&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Possible associations between elevated long-term cardiovascular risk and increasing dosage of ADHD treatment use in a young patient group should warrant further investigation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 14;83(19):1870-1882. doi: 10.1016/j.jacc.2024.03.375.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Incrementing numbers of patients treated for attention-deficit/hyperactivity disorder (ADHD) call for scrutiny concerning long-term drug-safety.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aims to investigate associations between long-term use of ADHD treatment and cardiovascular outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using nationwide registers, adult patients first-time initiated on ADHD treatment between 1998 and 2020 were identified. Exposure groups were prior users, &lt;1 defined daily dose (DDD) per day, ≥1 DDD per day determined at start of follow-up, and 1 year after patients' first claimed prescription. Outcomes were acute coronary syndromes, stroke, heart failure, and a composite of the above.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At start of follow-up, 26,357, 31,211, and 15,696 individuals were correspondingly categorized as prior users (42% female, median age: 30 years [Q1-Q3: 23-41 years]), &lt;1 DDD per day (47% female, median age: 31 years [Q1-Q3: 24-41 years]), and ≥1 DDD per day (47% female, median age: 33 years [Q1-Q3: 25-41 years]), respectively. Comparing ≥1 DDD per day with prior users, elevated standardized 10-year absolute risk of stroke (2.1% [95% CI: 1.8%-2.4%] vs 1.7% [95% CI: 1.5%-1.9%]), heart failure (1.2% [95% CI: 0.9%-1.4%] vs 0.7% [95% CI: 0.6%-0.8%]), and the composite outcome (3.9% [95% CI: 3.4%-4.3%] vs 3.0% [95% CI: 2.8 %-3.2%]) was found-with corresponding risk ratios of 1.2 (95% CI: 1.0-1.5), 1.7 (95% CI: 1.3-2.2), and 1.3 (95% CI: 1.1-1.5). No apparent associations were found for acute coronary syndrome (1.0% [95% CI: 0.8%-1.2%] vs 0.9% [95% CI: 0.8%-1.0%]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Possible associations between elevated long-term cardiovascular risk and increasing dosage of ADHD treatment use in a young patient group should warrant further investigation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38719367/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240509121035&v=2.18.0.post9+e462414">38719367</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.375>10.1016/j.jacc.2024.03.375</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38719367</guid>
<pubDate>Wed, 08 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Anders Holt</dc:creator>
<dc:creator>Jarl E Strange</dc:creator>
<dc:creator>Peter Vibe Rasmussen</dc:creator>
<dc:creator>Nina Nouhravesh</dc:creator>
<dc:creator>Sebastian Kinnberg Nielsen</dc:creator>
<dc:creator>Caroline Sindet-Pedersen</dc:creator>
<dc:creator>Emil Loldrup Fosbøl</dc:creator>
<dc:creator>Lars Køber</dc:creator>
<dc:creator>Christian Torp-Pedersen</dc:creator>
<dc:creator>Gunnar H Gislason</dc:creator>
<dc:creator>Patricia McGettigan</dc:creator>
<dc:creator>Morten Schou</dc:creator>
<dc:creator>Morten Lamberts</dc:creator>
<dc:date>2024-05-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Long-Term Cardiovascular Risk Associated With Treatment of Attention-Deficit/Hyperactivity Disorder in Adults</dc:title>
<dc:identifier>pmid:38719367</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.375</dc:identifier>
</item>
<item>
<title>Predictors of Arrhythmic Outcomes in Patients With Dilated and Nondilated Left Ventricular Cardiomyopathies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38719366/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240509121035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 14;83(19):1852-1854. doi: 10.1016/j.jacc.2024.03.404.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38719366/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240509121035&v=2.18.0.post9+e462414">38719366</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.404>10.1016/j.jacc.2024.03.404</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38719366</guid>
<pubDate>Wed, 08 May 2024 06:00:00 -0400</pubDate>
<dc:creator>John Gorcsan</dc:creator>
<dc:creator>Shunsuke Eguchi</dc:creator>
<dc:date>2024-05-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Predictors of Arrhythmic Outcomes in Patients With Dilated and Nondilated Left Ventricular Cardiomyopathies</dc:title>
<dc:identifier>pmid:38719366</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.404</dc:identifier>
</item>
<item>
<title>Magnetic Resonance Imaging Characterization and Clinical Outcomes of Dilated and Arrhythmogenic Left Ventricular Cardiomyopathies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38719365/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240509121035&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In a multicenter cohort of patients with DCM and NDLVC, septal LGE together with LV dilatation, age, advanced disease, and frequent and repetitive ventricular arrhythmias were powerful predictors of major arrhythmic events.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 14;83(19):1841-1851. doi: 10.1016/j.jacc.2024.02.041.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Nondilated left ventricular cardiomyopathy (NDLVC) has been recently differentiated from dilated cardiomyopathy (DCM). A comprehensive characterization of these 2 entities using cardiac magnetic resonance (CMR) and genetic testing has never been performed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to provide a thorough characterization and assess clinical outcomes in a large multicenter cohort of patients with DCM and NDLVC.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 462 patients with DCM (227) or NDLVC (235) with CMR data from 4 different referral centers were retrospectively analyzed. The study endpoint was a composite of sudden cardiac death or major ventricular arrhythmias.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In comparison to DCM, NDLVC had a higher prevalence of pathogenic or likely pathogenic variants of arrhythmogenic genes (40% vs 23%; P &lt; 0.001), higher left ventricular (LV) systolic function (LV ejection fraction: 51% ± 12% vs 36% ± 15%; P &lt; 0.001) and higher prevalence of free-wall late gadolinium enhancement (LGE) (27% vs 14%; P &lt; 0.001). Conversely, DCM showed higher prevalence of pathogenic or likely pathogenic variants of nonarrhythmogenic genes (23% vs 12%; P = 0.002) and septal LGE (45% vs 32%; P = 0.004). Over a median follow-up of 81 months (Q1-Q3: 40-132 months), the study outcome occurred in 98 (21%) patients. LGE with septal location (HR: 1.929; 95% CI: 1.033-3.601; P = 0.039) was independently associated with the risk of sudden cardiac death or major ventricular arrhythmias together with LV dilatation, older age, advanced NYHA functional class, frequent ventricular ectopic activity, and nonsustained ventricular tachycardia.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In a multicenter cohort of patients with DCM and NDLVC, septal LGE together with LV dilatation, age, advanced disease, and frequent and repetitive ventricular arrhythmias were powerful predictors of major arrhythmic events.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38719365/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240509121035&v=2.18.0.post9+e462414">38719365</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.041>10.1016/j.jacc.2024.02.041</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38719365</guid>
<pubDate>Wed, 08 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Matteo Castrichini</dc:creator>
<dc:creator>Antonio De Luca</dc:creator>
<dc:creator>Giulia De Angelis</dc:creator>
<dc:creator>Raquel Neves</dc:creator>
<dc:creator>Alessia Paldino</dc:creator>
<dc:creator>Matteo Dal Ferro</dc:creator>
<dc:creator>Giulia Barbati</dc:creator>
<dc:creator>Kristen Medo</dc:creator>
<dc:creator>Andrea Barison</dc:creator>
<dc:creator>Chrysanthos Grigoratos</dc:creator>
<dc:creator>Marta Gigli</dc:creator>
<dc:creator>Davide Stolfo</dc:creator>
<dc:creator>Francesca Brun</dc:creator>
<dc:creator>Daniel W Groves</dc:creator>
<dc:creator>Robert Quaife</dc:creator>
<dc:creator>Ramone Eldemire</dc:creator>
<dc:creator>Sharon Graw</dc:creator>
<dc:creator>Jeffrey Addison</dc:creator>
<dc:creator>Giancarlo Todiere</dc:creator>
<dc:creator>Ignazio Alessio Gueli</dc:creator>
<dc:creator>Nicoletta Botto</dc:creator>
<dc:creator>Michele Emdin</dc:creator>
<dc:creator>Giovanni Donato Aquaro</dc:creator>
<dc:creator>Ramin Garmany</dc:creator>
<dc:creator>Naveen L Pereira</dc:creator>
<dc:creator>Matthew R G Taylor</dc:creator>
<dc:creator>Michael J Ackerman</dc:creator>
<dc:creator>Gianfranco Sinagra</dc:creator>
<dc:creator>Luisa Mestroni</dc:creator>
<dc:creator>John R Giudicessi</dc:creator>
<dc:creator>Marco Merlo</dc:creator>
<dc:date>2024-05-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Magnetic Resonance Imaging Characterization and Clinical Outcomes of Dilated and Arrhythmogenic Left Ventricular Cardiomyopathies</dc:title>
<dc:identifier>pmid:38719365</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.041</dc:identifier>
</item>
<item>
<title>The Hidden Cardiovascular Crisis Among Former NFL Athletes: After the HUDDLE</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38719364/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240509121035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 14;83(19):1838-1840. doi: 10.1016/j.jacc.2024.03.403.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38719364/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240509121035&v=2.18.0.post9+e462414">38719364</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.403>10.1016/j.jacc.2024.03.403</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38719364</guid>
<pubDate>Wed, 08 May 2024 06:00:00 -0400</pubDate>
<dc:creator>J Sawalla Guseh</dc:creator>
<dc:creator>James L Januzzi</dc:creator>
<dc:date>2024-05-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Hidden Cardiovascular Crisis Among Former NFL Athletes: After the HUDDLE</dc:title>
<dc:identifier>pmid:38719364</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.403</dc:identifier>
</item>
<item>
<title>2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38718139/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240509121035&amp;v=2.18.0.post9+e462414
      <description>AIM: The "2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy" provides recommendations to guide clinicians in the management of patients with hypertrophic cardiomyopathy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 8. doi: 10.1161/CIR.0000000000001250. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">AIM: The "2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy" provides recommendations to guide clinicians in the management of patients with hypertrophic cardiomyopathy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A comprehensive literature search was conducted from September 14, 2022, to November 22, 2022, encompassing studies, reviews, and other evidence on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through May 23, 2023, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">STRUCTURE: Hypertrophic cardiomyopathy remains a common genetic heart disease reported in populations globally. Recommendations from the "2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy" have been updated with new evidence to guide clinicians.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38718139/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240509121035&v=2.18.0.post9+e462414">38718139</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001250>10.1161/CIR.0000000000001250</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38718139</guid>
<pubDate>Wed, 08 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Steve R Ommen</dc:creator>
<dc:creator>Carolyn Y Ho</dc:creator>
<dc:creator>Irfan M Asif</dc:creator>
<dc:creator>Seshadri Balaji</dc:creator>
<dc:creator>Michael A Burke</dc:creator>
<dc:creator>Sharlene M Day</dc:creator>
<dc:creator>Joseph A Dearani</dc:creator>
<dc:creator>Kelly C Epps</dc:creator>
<dc:creator>Lauren Evanovich</dc:creator>
<dc:creator>Victor A Ferrari</dc:creator>
<dc:creator>José A Joglar</dc:creator>
<dc:creator>Sadiya S Khan</dc:creator>
<dc:creator>Jeffrey J Kim</dc:creator>
<dc:creator>Michelle M Kittleson</dc:creator>
<dc:creator>Chayakrit Krittanawong</dc:creator>
<dc:creator>Matthew W Martinez</dc:creator>
<dc:creator>Seema Mital</dc:creator>
<dc:creator>Srihari S Naidu</dc:creator>
<dc:creator>Sara Saberi</dc:creator>
<dc:creator>Christopher Semsarian</dc:creator>
<dc:creator>Sabrina Times</dc:creator>
<dc:creator>Cynthia Burstein Waldman</dc:creator>
<dc:date>2024-05-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines</dc:title>
<dc:identifier>pmid:38718139</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001250</dc:identifier>
</item>
<item>
<title>Underrepresentation of Women in Revascularization Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38717765/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240509121035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 May 8. doi: 10.1001/jamacardio.2024.0768. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38717765/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240509121035&v=2.18.0.post9+e462414">38717765</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0768>10.1001/jamacardio.2024.0768</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38717765</guid>
<pubDate>Wed, 08 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Celina M Yong</dc:creator>
<dc:creator>William F Fearon</dc:creator>
<dc:date>2024-05-08</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Underrepresentation of Women in Revascularization Trials</dc:title>
<dc:identifier>pmid:38717765</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0768</dc:identifier>
</item>
<item>
<title>Complete vs Culprit-Only Revascularization in Older Patients With Myocardial Infarction and High Bleeding Risk: A Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38717753/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240509121035&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: HBR status is prevalent among older patients with MI, significantly increasing the likelihood of adverse events. Physiology-guided complete revascularization emerges as an effective strategy, in comparison with culprit-only revascularization, for mitigating ischemic adverse events, including cardiovascular death and MI.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 May 8. doi: 10.1001/jamacardio.2024.0804. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Patients with high bleeding risk (HBR) have a poor prognosis, and it is not known if they may benefit from complete revascularization after myocardial infarction (MI).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To investigate the benefit of physiology-guided complete revascularization vs a culprit-only strategy in patients with HBR, MI, and multivessel disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a prespecified analysis of the Functional Assessment in Elderly MI Patients With Multivessel Disease (FIRE) randomized clinical trial data. FIRE was an investigator-initiated, open-label, multicenter trial. Patients 75 years or older with MI and multivessel disease were enrolled at 34 European centers from July 2019 through October 2021. Physiology treatment was performed either by angiography- or wire-based assessment. Patients were divided into HBR or non-HBR categories in accordance with the Academic Research Consortium HBR document.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Patients were randomized to either physiology-guided complete revascularization or culprit-only strategy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome comprised a composite of death, MI, stroke, or revascularization at 1 year. Secondary outcomes included a composite of cardiovascular death or MI and Bleeding Academic Research Consortium (BARC) types 3 to 5.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 1445 patients (mean [SD] age, 81 [5] years; 917 male [63%]), 1025 (71%) met HBR criteria. Patients with HBR were at higher risk for the primary end point (hazard ratio [HR], 2.01; 95% CI, 1.47-2.76), cardiovascular death or MI (HR, 1.89; 95% CI, 1.26-2.83), and BARC types 3 to 5 (HR, 3.28; 95% CI, 1.40-7.64). The primary end point was significantly reduced with physiology-guided complete revascularization as compared with culprit-only strategy in patients with HBR (HR, 0.73; 95% CI, 0.55-0.96). No indication of interaction was noted between revascularization strategy and HBR status for primary and secondary end points.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: HBR status is prevalent among older patients with MI, significantly increasing the likelihood of adverse events. Physiology-guided complete revascularization emerges as an effective strategy, in comparison with culprit-only revascularization, for mitigating ischemic adverse events, including cardiovascular death and MI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03772743.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38717753/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240509121035&v=2.18.0.post9+e462414">38717753</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0804>10.1001/jamacardio.2024.0804</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38717753</guid>
<pubDate>Wed, 08 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Andrea Erriquez</dc:creator>
<dc:creator>Gianluca Campo</dc:creator>
<dc:creator>Vincenzo Guiducci</dc:creator>
<dc:creator>Javier Escaned</dc:creator>
<dc:creator>Raul Moreno</dc:creator>
<dc:creator>Gianni Casella</dc:creator>
<dc:creator>Mila Menozzi</dc:creator>
<dc:creator>Enrico Cerrato</dc:creator>
<dc:creator>Giorgio Sacchetta</dc:creator>
<dc:creator>Alberto Menozzi</dc:creator>
<dc:creator>Ignacio Amat Santos</dc:creator>
<dc:creator>Enrique Gutiérrez Ibañes</dc:creator>
<dc:creator>Roberto Scarsini</dc:creator>
<dc:creator>Giuseppe Vadalà</dc:creator>
<dc:creator>Giuseppe Andò</dc:creator>
<dc:creator>José Luis Díez-Gil</dc:creator>
<dc:creator>Sergio Musto d'Amore</dc:creator>
<dc:creator>Alessandro Capecchi</dc:creator>
<dc:creator>Iginio Colaiori</dc:creator>
<dc:creator>Francesco Gallo</dc:creator>
<dc:creator>Rita Pavasini</dc:creator>
<dc:creator>Andrea Marrone</dc:creator>
<dc:creator>Graziella Pompei</dc:creator>
<dc:creator>Valerio Lanzilotti</dc:creator>
<dc:creator>Dariusz Dudek</dc:creator>
<dc:creator>Emanuele Barbato</dc:creator>
<dc:creator>Matteo Tebaldi</dc:creator>
<dc:creator>Simone Biscaglia</dc:creator>
<dc:date>2024-05-08</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Complete vs Culprit-Only Revascularization in Older Patients With Myocardial Infarction and High Bleeding Risk: A Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:38717753</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0804</dc:identifier>
</item>
<item>
<title>Error in Table 1</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38717750/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240509121035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 May 8. doi: 10.1001/jamacardio.2024.1123. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38717750/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240509121035&v=2.18.0.post9+e462414">38717750</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1123>10.1001/jamacardio.2024.1123</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38717750</guid>
<pubDate>Wed, 08 May 2024 06:00:00 -0400</pubDate>
<dc:date>2024-05-08</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Error in Table 1</dc:title>
<dc:identifier>pmid:38717750</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1123</dc:identifier>
</item>
<item>
<title>Cardiac biomarkers for diagnosing Takotsubo syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38717630/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240509121035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 8:ehae231. doi: 10.1093/eurheartj/ehae231. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38717630/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240509121035&v=2.18.0.post9+e462414">38717630</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae231>10.1093/eurheartj/ehae231</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38717630</guid>
<pubDate>Wed, 08 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Victor Schweiger</dc:creator>
<dc:creator>Davide Di Vece</dc:creator>
<dc:creator>Victoria L Cammann</dc:creator>
<dc:creator>Iva Koleva</dc:creator>
<dc:creator>Michael Würdinger</dc:creator>
<dc:creator>Thomas Gilhofer</dc:creator>
<dc:creator>Katja Rajman</dc:creator>
<dc:creator>Konrad A Szawan</dc:creator>
<dc:creator>David Niederseer</dc:creator>
<dc:creator>Rodolfo Citro</dc:creator>
<dc:creator>Carmine Vecchione</dc:creator>
<dc:creator>Eduardo Bossone</dc:creator>
<dc:creator>Sebastiano Gili</dc:creator>
<dc:creator>Michael Neuhaus</dc:creator>
<dc:creator>Jennifer Franke</dc:creator>
<dc:creator>Benjamin Meder</dc:creator>
<dc:creator>Miłosz Jaguszewski</dc:creator>
<dc:creator>Michel Noutsias</dc:creator>
<dc:creator>Maike Knorr</dc:creator>
<dc:creator>Thomas Jansen</dc:creator>
<dc:creator>Fabrizio D'Ascenzo</dc:creator>
<dc:creator>Francesco Bruno</dc:creator>
<dc:creator>Ovidio De Filippo</dc:creator>
<dc:creator>Giulio Stefanini</dc:creator>
<dc:creator>Gianluca Campo</dc:creator>
<dc:creator>Wojciech Wanha</dc:creator>
<dc:creator>Sergio Raposeiras Roubin</dc:creator>
<dc:creator>Wolfgang Dichtl</dc:creator>
<dc:creator>Dirk von Lewinski</dc:creator>
<dc:creator>Christof Burgdorf</dc:creator>
<dc:creator>Behrouz Kherad</dc:creator>
<dc:creator>Carsten Tschöpe</dc:creator>
<dc:creator>Annahita Sarcon</dc:creator>
<dc:creator>Jerold Shinbane</dc:creator>
<dc:creator>Lawrence Rajan</dc:creator>
<dc:creator>Guido Michels</dc:creator>
<dc:creator>Roman Pfister</dc:creator>
<dc:creator>Alessandro Cuneo</dc:creator>
<dc:creator>Claudius Jacobshagen</dc:creator>
<dc:creator>Mahir Karakas</dc:creator>
<dc:creator>Wolfgang Koenig</dc:creator>
<dc:creator>Alexander Pott</dc:creator>
<dc:creator>Philippe Meyer</dc:creator>
<dc:creator>Marco Roffi</dc:creator>
<dc:creator>Adrian Banning</dc:creator>
<dc:creator>Mathias Wolfrum</dc:creator>
<dc:creator>Florim Cuculi</dc:creator>
<dc:creator>Richard Kobza</dc:creator>
<dc:creator>Thomas A Fischer</dc:creator>
<dc:creator>Tuija Vasankari</dc:creator>
<dc:creator>K E Juhani Airaksinen</dc:creator>
<dc:creator>L Christian Napp</dc:creator>
<dc:creator>Rafal Dworakowski</dc:creator>
<dc:creator>Philip MacCarthy</dc:creator>
<dc:creator>Christoph Kaiser</dc:creator>
<dc:creator>Stefan Osswald</dc:creator>
<dc:creator>Leonarda Galiuto</dc:creator>
<dc:creator>Christina Chan</dc:creator>
<dc:creator>Paul Bridgman</dc:creator>
<dc:creator>Daniel Beug</dc:creator>
<dc:creator>Clément Delmas</dc:creator>
<dc:creator>Olivier Lairez</dc:creator>
<dc:creator>Ekaterina Gilyarova</dc:creator>
<dc:creator>Alexandra Shilova</dc:creator>
<dc:creator>Mikhail Gilyarov</dc:creator>
<dc:creator>Ibrahim El-Battrawy</dc:creator>
<dc:creator>Ibrahim Akin</dc:creator>
<dc:creator>Karolina Poledniková</dc:creator>
<dc:creator>Petr Toušek</dc:creator>
<dc:creator>David E Winchester</dc:creator>
<dc:creator>Michael Massoomi</dc:creator>
<dc:creator>Jan Galuszka</dc:creator>
<dc:creator>Christian Ukena</dc:creator>
<dc:creator>Gregor Poglajen</dc:creator>
<dc:creator>Pedro Carrilho-Ferreira</dc:creator>
<dc:creator>Christian Hauck</dc:creator>
<dc:creator>Carla Paolini</dc:creator>
<dc:creator>Claudio Bilato</dc:creator>
<dc:creator>Yoshio Kobayashi</dc:creator>
<dc:creator>Ken Kato</dc:creator>
<dc:creator>Iwao Ishibashi</dc:creator>
<dc:creator>Toshiharu Himi</dc:creator>
<dc:creator>Jehangir Din</dc:creator>
<dc:creator>Ali Al-Shammari</dc:creator>
<dc:creator>Abhiram Prasad</dc:creator>
<dc:creator>Charanjit S Rihal</dc:creator>
<dc:creator>Kan Liu</dc:creator>
<dc:creator>P Christian Schulze</dc:creator>
<dc:creator>Matteo Bianco</dc:creator>
<dc:creator>Lucas Jörg</dc:creator>
<dc:creator>Hans Rickli</dc:creator>
<dc:creator>Gonçalo Pestana</dc:creator>
<dc:creator>Thanh H Nguyen</dc:creator>
<dc:creator>Michael Böhm</dc:creator>
<dc:creator>Lars S Maier</dc:creator>
<dc:creator>Fausto J Pinto</dc:creator>
<dc:creator>Petr Widimský</dc:creator>
<dc:creator>Stephan B Felix</dc:creator>
<dc:creator>Ruediger C Braun-Dullaeus</dc:creator>
<dc:creator>Wolfgang Rottbauer</dc:creator>
<dc:creator>Gerd Hasenfuß</dc:creator>
<dc:creator>Burkert M Pieske</dc:creator>
<dc:creator>Heribert Schunkert</dc:creator>
<dc:creator>Monika Budnik</dc:creator>
<dc:creator>Grzegorz Opolski</dc:creator>
<dc:creator>Holger Thiele</dc:creator>
<dc:creator>Johann Bauersachs</dc:creator>
<dc:creator>John D Horowitz</dc:creator>
<dc:creator>Carlo Di Mario</dc:creator>
<dc:creator>William Kong</dc:creator>
<dc:creator>Mayank Dalakoti</dc:creator>
<dc:creator>Yoichi Imori</dc:creator>
<dc:creator>Thomas Münzel</dc:creator>
<dc:creator>Jeroen J Bax</dc:creator>
<dc:creator>Thomas F Lüscher</dc:creator>
<dc:creator>Filippo Crea</dc:creator>
<dc:creator>Frank Ruschitzka</dc:creator>
<dc:creator>Jelena R Ghadri</dc:creator>
<dc:creator>Christian Templin</dc:creator>
<dc:date>2024-05-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardiac biomarkers for diagnosing Takotsubo syndrome</dc:title>
<dc:identifier>pmid:38717630</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae231</dc:identifier>
</item>
<item>
<title>JAMA Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38717512/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240509121035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 May 1;9(5). doi: 10.1001/jamacardio.2023.3659.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38717512/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240509121035&v=2.18.0.post9+e462414">38717512</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3659>10.1001/jamacardio.2023.3659</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38717512</guid>
<pubDate>Wed, 08 May 2024 06:00:00 -0400</pubDate>
<dc:date>2024-05-08</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>JAMA Cardiology</dc:title>
<dc:identifier>pmid:38717512</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3659</dc:identifier>
</item>
<item>
<title>Mapping the cellular biogeography of human bone marrow niches using single-cell transcriptomics and proteomic imaging</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38714197/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240509121035&amp;v=2.18.0.post9+e462414
      <description>Non-hematopoietic cells are essential contributors to hematopoiesis. However, heterogeneity and spatial organization of these cells in human bone marrow remain largely uncharacterized. We used single-cell RNA sequencing (scRNA-seq) to profile 29,325 non-hematopoietic cells and discovered nine transcriptionally distinct subtypes. We simultaneously profiled 53,417 hematopoietic cells and predicted their interactions with non-hematopoietic subsets. We employed co-detection by indexing (CODEX) to...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 May 2:S0092-8674(24)00408-2. doi: 10.1016/j.cell.2024.04.013. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Non-hematopoietic cells are essential contributors to hematopoiesis. However, heterogeneity and spatial organization of these cells in human bone marrow remain largely uncharacterized. We used single-cell RNA sequencing (scRNA-seq) to profile 29,325 non-hematopoietic cells and discovered nine transcriptionally distinct subtypes. We simultaneously profiled 53,417 hematopoietic cells and predicted their interactions with non-hematopoietic subsets. We employed co-detection by indexing (CODEX) to spatially profile over 1.2 million cells. We integrated scRNA-seq and CODEX data to link predicted cellular signaling with spatial proximity. Our analysis revealed a hyperoxygenated arterio-endosteal neighborhood for early myelopoiesis, and an adipocytic localization for early hematopoietic stem and progenitor cells (HSPCs). We used our CODEX atlas to annotate new images and uncovered mesenchymal stromal cell (MSC) expansion and spatial neighborhoods co-enriched for leukemic blasts and MSCs in acute myeloid leukemia (AML) patient samples. This spatially resolved, multiomic atlas of human bone marrow provides a reference for investigation of cellular interactions that drive hematopoiesis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38714197/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240509121035&v=2.18.0.post9+e462414">38714197</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.04.013>10.1016/j.cell.2024.04.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38714197</guid>
<pubDate>Tue, 07 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Shovik Bandyopadhyay</dc:creator>
<dc:creator>Michael P Duffy</dc:creator>
<dc:creator>Kyung Jin Ahn</dc:creator>
<dc:creator>Jonathan H Sussman</dc:creator>
<dc:creator>Minxing Pang</dc:creator>
<dc:creator>David Smith</dc:creator>
<dc:creator>Gwendolyn Duncan</dc:creator>
<dc:creator>Iris Zhang</dc:creator>
<dc:creator>Jeffrey Huang</dc:creator>
<dc:creator>Yulieh Lin</dc:creator>
<dc:creator>Barbara Xiong</dc:creator>
<dc:creator>Tamjid Imtiaz</dc:creator>
<dc:creator>Chia-Hui Chen</dc:creator>
<dc:creator>Anusha Thadi</dc:creator>
<dc:creator>Changya Chen</dc:creator>
<dc:creator>Jason Xu</dc:creator>
<dc:creator>Melissa Reichart</dc:creator>
<dc:creator>Zachary Martinez</dc:creator>
<dc:creator>Caroline Diorio</dc:creator>
<dc:creator>Chider Chen</dc:creator>
<dc:creator>Vinodh Pillai</dc:creator>
<dc:creator>Oraine Snaith</dc:creator>
<dc:creator>Derek Oldridge</dc:creator>
<dc:creator>Siddharth Bhattacharyya</dc:creator>
<dc:creator>Ivan Maillard</dc:creator>
<dc:creator>Martin Carroll</dc:creator>
<dc:creator>Charles Nelson</dc:creator>
<dc:creator>Ling Qin</dc:creator>
<dc:creator>Kai Tan</dc:creator>
<dc:date>2024-05-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Mapping the cellular biogeography of human bone marrow niches using single-cell transcriptomics and proteomic imaging</dc:title>
<dc:identifier>pmid:38714197</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.04.013</dc:identifier>
</item>
<item>
<title>Non-traditional risk factors: built environment assessed by Google Street View, syphilis, and rheumatoid arthritis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38713840/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240509121035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 7;45(17):1489-1493. doi: 10.1093/eurheartj/ehae261.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38713840/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240509121035&v=2.18.0.post9+e462414">38713840</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae261>10.1093/eurheartj/ehae261</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38713840</guid>
<pubDate>Tue, 07 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-05-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Non-traditional risk factors: built environment assessed by Google Street View, syphilis, and rheumatoid arthritis</dc:title>
<dc:identifier>pmid:38713840</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae261</dc:identifier>
</item>
<item>
<title>Rheumatoid arthritis and peripartum cardiovascular complications: focusing on non-traditional cardiovascular risk factors to improve maternal outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38713839/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240509121035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 7;45(17):1537-1539. doi: 10.1093/eurheartj/ehae164.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38713839/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240509121035&v=2.18.0.post9+e462414">38713839</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae164>10.1093/eurheartj/ehae164</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38713839</guid>
<pubDate>Tue, 07 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Sarah Goldstein</dc:creator>
<dc:creator>Kathryn Lindley</dc:creator>
<dc:date>2024-05-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Rheumatoid arthritis and peripartum cardiovascular complications: focusing on non-traditional cardiovascular risk factors to improve maternal outcomes</dc:title>
<dc:identifier>pmid:38713839</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae164</dc:identifier>
</item>
<item>
<title>Ultrasound Neuromodulation of an Anti-Inflammatory Pathway at the Spleen Improves Experimental Pulmonary Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38712557/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240509121035&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: sFUS causes dose-dependent, sustained improvement of hemodynamic, autonomic, laboratory, and pathological manifestations in 2 models of experimental pulmonary hypertension. Mechanistically, sFUS normalizes immune cell populations in the spleen and downregulates inflammatory genes and pathways in the lung, many of which are relevant in human disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 May 7. doi: 10.1161/CIRCRESAHA.123.323679. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Inflammation is pathogenically implicated in pulmonary arterial hypertension; however, it has not been adequately targeted therapeutically. We investigated whether neuromodulation of an anti-inflammatory neuroimmune pathway involving the splenic nerve using noninvasive, focused ultrasound stimulation of the spleen (sFUS) can improve experimental pulmonary hypertension.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Pulmonary hypertension was induced in rats either by Sugen 5416 (20 mg/kg SQ) injection, followed by 21 (or 35) days of hypoxia (sugen/hypoxia model), or by monocrotaline (60 mg/kg IP) injection (monocrotaline model). Animals were randomized to receive either 12-minute-long sessions of sFUS daily or sham stimulation for 14 days. Catheterizations, echocardiography, indices of autonomic function, lung and heart histology and immunohistochemistry, spleen flow cytometry, and lung single-cell RNA sequencing were performed after treatment to assess the effects of sFUS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Splenic denervation right before induction of pulmonary hypertension results in a more severe disease phenotype. In both sugen/hypoxia and monocrotaline models, sFUS treatment reduces right ventricular systolic pressure by 25% to 30% compared with sham treatment, without affecting systemic pressure, and improves right ventricular function and autonomic indices. sFUS reduces wall thickness, apoptosis, and proliferation in small pulmonary arterioles, suppresses CD3<sup>+</sup> and CD68<sup>+</sup> cell infiltration in lungs and right ventricular fibrosis and hypertrophy and lowers BNP (brain natriuretic peptide). Beneficial effects persist for weeks after sFUS discontinuation and are more robust with early and longer treatment. Splenic denervation abolishes sFUS therapeutic benefits. sFUS partially normalizes CD68<sup>+</sup> and CD8<sup>+</sup> T-cell counts in the spleen and downregulates several inflammatory genes and pathways in nonclassical and classical monocytes and macrophages in the lung. Differentially expressed genes in those cell types are significantly enriched for human pulmonary arterial hypertension-associated genes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: sFUS causes dose-dependent, sustained improvement of hemodynamic, autonomic, laboratory, and pathological manifestations in 2 models of experimental pulmonary hypertension. Mechanistically, sFUS normalizes immune cell populations in the spleen and downregulates inflammatory genes and pathways in the lung, many of which are relevant in human disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38712557/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240509121035&v=2.18.0.post9+e462414">38712557</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323679>10.1161/CIRCRESAHA.123.323679</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38712557</guid>
<pubDate>Tue, 07 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Stefanos Zafeiropoulos</dc:creator>
<dc:creator>Umair Ahmed</dc:creator>
<dc:creator>Alexandra Bekiaridou</dc:creator>
<dc:creator>Naveen Jayaprakash</dc:creator>
<dc:creator>Ibrahim T Mughrabi</dc:creator>
<dc:creator>Nafiseh Saleknezhad</dc:creator>
<dc:creator>Chrystal Chadwick</dc:creator>
<dc:creator>Anna Daytz</dc:creator>
<dc:creator>Izumi Kurata-Sato</dc:creator>
<dc:creator>Yemil Atish-Fregoso</dc:creator>
<dc:creator>Kaitlin Carroll</dc:creator>
<dc:creator>Yousef Al-Abed</dc:creator>
<dc:creator>Marat Fudim</dc:creator>
<dc:creator>Christopher Puleo</dc:creator>
<dc:creator>George Giannakoulas</dc:creator>
<dc:creator>Mark Nicolls</dc:creator>
<dc:creator>Betty Diamond</dc:creator>
<dc:creator>Stavros Zanos</dc:creator>
<dc:date>2024-05-07</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Ultrasound Neuromodulation of an Anti-Inflammatory Pathway at the Spleen Improves Experimental Pulmonary Hypertension</dc:title>
<dc:identifier>pmid:38712557</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323679</dc:identifier>
</item>
<item>
<title>Illusion of revascularization: does anyone achieve optimal revascularization during percutaneous coronary intervention?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38710772/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240509121035&amp;v=2.18.0.post9+e462414
      <description>This Perspective article is a form of 'pastiche', inspired by the 1993 review by Lincoff and Topol entitled 'Illusion of reperfusion', and explores how their concept continues to apply to percutaneous revascularization in patients with coronary artery disease and ischaemia. Just as Lincoff and Topol argued that reperfusion of acute myocardial infarction was facing unresolved obstacles that hampered clinical success in 1993, we propose that challenging issues are similarly jeopardizing the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 May 7. doi: 10.1038/s41569-024-01014-0. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">This Perspective article is a form of 'pastiche', inspired by the 1993 review by Lincoff and Topol entitled 'Illusion of reperfusion', and explores how their concept continues to apply to percutaneous revascularization in patients with coronary artery disease and ischaemia. Just as Lincoff and Topol argued that reperfusion of acute myocardial infarction was facing unresolved obstacles that hampered clinical success in 1993, we propose that challenging issues are similarly jeopardizing the potential benefits of stent-based angioplasty today. By analysing the appropriateness and efficacy of percutaneous coronary intervention (PCI), we emphasize the limitations of relying solely on visual angiographic guidance, which frequently leads to inappropriate stenting and overtreatment in up to one-third of patients and the associated increased risk of periprocedural myocardial infarction. The lack of optimal revascularization observed in half of patients undergoing PCI confers risks such as suboptimal physiology after PCI, residual angina and long-term stent-related events, leaving an estimated 76% of patients with an 'illusion of revascularization'. These outcomes highlight the need to refine our diagnostic tools by integrating physiological assessments with targeted intracoronary imaging and emerging strategies, such as co-registration systems and angiography-based computational methods enhanced by artificial intelligence, to achieve optimal revascularization outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38710772/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240509121035&v=2.18.0.post9+e462414">38710772</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01014-0>10.1038/s41569-024-01014-0</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38710772</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Simone Fezzi</dc:creator>
<dc:creator>Daixin Ding</dc:creator>
<dc:creator>Felix Mahfoud</dc:creator>
<dc:creator>Jiayue Huang</dc:creator>
<dc:creator>Alexandra J Lansky</dc:creator>
<dc:creator>Shengxian Tu</dc:creator>
<dc:creator>William Wijns</dc:creator>
<dc:date>2024-05-06</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Illusion of revascularization: does anyone achieve optimal revascularization during percutaneous coronary intervention?</dc:title>
<dc:identifier>pmid:38710772</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01014-0</dc:identifier>
</item>
<item>
<title>Correction to: 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38709844/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240509121035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 7;149(19):e1164. doi: 10.1161/CIR.0000000000001247. Epub 2024 May 6.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38709844/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240509121035&v=2.18.0.post9+e462414">38709844</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001247>10.1161/CIR.0000000000001247</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38709844</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:date>2024-05-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association</dc:title>
<dc:identifier>pmid:38709844</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001247</dc:identifier>
</item>





























</channel>
</rss>